Bayer’s Kerendia cuts heart death, failure and hospitalization by 16% in Phase 3 trial
Less than a month after announcing success in a late-phase trial, Bayer has unveiled detailed results from its drug Kerendia in a subset of people …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
